COMPASS Pathways plc (NASDAQ:CMPS) Given Average Rating of “Buy” by Brokerages

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been given an average recommendation of “Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $21.83.

CMPS has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a research note on Friday. Canaccord Genuity Group lowered their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus initiated coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective for the company.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently made changes to their positions in CMPS. China Universal Asset Management Co. Ltd. purchased a new position in COMPASS Pathways in the fourth quarter valued at about $41,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $43,000. Flagship Harbor Advisors LLC acquired a new position in COMPASS Pathways during the 4th quarter worth approximately $43,000. Conservest Capital Advisors Inc. boosted its holdings in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after acquiring an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. acquired a new stake in COMPASS Pathways in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $2.94 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The firm has a market cap of $272.46 million, a PE ratio of -1.34 and a beta of 2.29. The firm has a 50 day simple moving average of $3.86 and a 200-day simple moving average of $4.72. COMPASS Pathways has a 1-year low of $2.88 and a 1-year high of $10.31.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.